This is the authors' abstract. We don't add key points for this paper.
Polymers play important roles in the design of delivery nanocarriers for cancer therapies. Polymeric nanocarriers with anticancer drugs conjugated or encapsulated, also known as polymeric nanomedicines, form a variety of different architectures including polymer‐drug conjugates, micelles, nanospheres, nanogels, vesicles, and dendrimers. This review focuses on the current state of the preclinical and clinical investigations of polymer‐drug conjugates and polymeric micelles. Recent progress achieved in some promising fields, such as site‐specific protein conjugation, pH‐sensitive polymer‐drug conjugates, polymer nanoparticles for targeted cancer therapy, stimuli‐responsive polymeric micelles, polymeric vesicles, and dendrimer‐based anticancer nanomedicines, will be highlighted.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: